Omnes Capital — 2013 Investments
4 investments dated 2013 · listed companies and verified rows first · show all
Complix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions.
AI & Machine LearningBiotechDeep TechMedical Devices
Co-investorsPMVAndera PartnersVesalius Biocapital PartnersGimv
Co-investorsFountain Healthcare Partners
Pixium Vision SA developed the PRIMA System, an implantable device for treating late-stage macular degeneration, and ran clinical trials in Europe.
BiotechHealthtechMedical Devices
Co-investorsAgoranovSofinnova PartnersAbingworthBpifrance
TISSIUM develops biomorphic polymer technology, including proprietary polymers, activation technologies, and delivery devices, to reconstruct damaged tissue and restore its function across multiple therapeutic areas.
BiotechDeep TechMedical DevicesNew Materials
Christophe Bancel(Co-founder & CEO)inMaria Pereira(Co-inventor of the technology; leads the Innovation Hub)in
Co-investorsCapDecisif ManagementCathay HealthKaristaSofinnova PartnersCathay InnovationEuropean Investment Bank
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.








